After completing a PhD in medicinal chemistry and quantum physics at Ecole Normale Superieure in Paris, Gilles Rubinstenn joined L’OREAL R&D in 1998 where he learned scientific management and innovation (becoming inventor in 34 patents, including the formulation supporting the $2B Lancôme Absolue® franchise). After leading the innovation team of EUROTAB and establishing the Pierre-Gilles de Gennes Foundation, he has chaired the SATT idfinnov (now erganeo) a private tech-transfer office and seed investment agency operating over the largest biomedical cluster of the Paris area. In 2013, together with 3 partners he co-founded M2i Life Sciences, which became within 6 years a world leader for biocontrol, replacing pesticides with insects’ pheromones, and closed one of the largest 2019 French Tech Investment round. In M2i, Gilles has held various positions, first restructuring the marketing teams, them leading the Pharma business unit and finally acting as CFO supporting the successful conclusion of the M2i round B and post-closing operations. Since 2018 he has been working at building the foundation of ReST while advising the President of AFM TELETHON on Bioproduction. Gilles Rubinstenn holds an EMBA from INSEAD and teaches entrepreneurship in various business Schools.

Florent Perin-Dureau graduated from the Ecole Normale Superieure – Sorbonne University joined MD- MsC program in 2004. His research Thesis was on the neuropharmacology of NMDA receptors. He then became assistant professor in anesthesiology and neurointensive care at hospital Pitie-Salpetriere. He practiced as senior intensivist in Foundation Rothschild and hospital Foch. He was there specifically in charge of supporting critical care patient’s families through their trauma. Florent completed his formation with a master in strategy and management of health industries at ESSEC business school and was then appointed Director of the largest ANSM division supervising drug MA, including neurology, psychiatry, anesthesiology, pain medicine, as well as respiratory medicine, rheumatology, and internal medicine. He then returned to hospital Foch as Head of Clinical Research Department  (Phase II-III trials but also Phase I, sponsored by industry and investigator-driven protocols). Since 2017, Florent has been consulting with the pharmaceutical industry, advising mainly in clinical development and market authorization process while becoming involved in the biotech start-up ecosystem. He first repositioned a spin-off of Institute Pasteur, dedicated to stem cell and regenerative medicine, then joining the management team of ReST.

Aude holds a master’s degree in microbiology (2004) at the university of Dijon and joined Dow AgroSciences to experiments phytosanitary products in order to adapt their use and support farmers in their production. She learned to manage experiments prior joining the plant protection association to train winegrowers in vine diseases and orient their practices towards sustainable agriculture. In 2008, she decided to orient her career in the health field and joined many companies in medical device industry and/or pharmaceutical industry. First position was trainee at Urgo Medical where she learned the basics of clinical research prior joining the medical department of Coloplast where she consolidated knowledge and skills in clinical research and medical devices (class I and class II). From 2010 to 2012, she conducted clinical studies for Quintiles IMS dedicated to Pfizer laboratory in oncology, rheumatology, pediatrics and rare diseases. For 7 years, she held various positions in scientific & clinical affairs department of BBraun Medical in the preclinical and clinical development strategy of medical devices (class I to class III) and the implementation of clinical studies on medical devices and drugs. In 2019, Aude had the desire to discover the start-up environment and joined Quantum Surgical to lead the preclinical and clinical activities to get the CE marked of the robotized device prior joining ReST Therapeutics.